(September 2008)
The graphs report the preliminary analysis of data sent to the RBDD.
Data were obtained from the compiled joining forms of the RBDD project.
The compilation of the joining forms is not under our control and we are not responsible for the content (including the accuracy) of any form.
The total number includes patients affected by different degrees of severity.
Figure 6	reports the geographic distribution of centres that have already joined the database (already joined).
Figure 7	reports the total number and percentages of patients affected by each deficiency.
Figure 8	reports the percentages of patients affected by RBDs in different regions of the world.
Figure 9	reports treatments available in different regions of the world.
Figure 10	reports available treatments for each deficiency in different regions of the world.
Figure 11	reports the percentages of existing problems in the treatment of patients affected with RBDs in different region of the world.
Since we have data from only one centre in Oceania, these data are not included in our analysis. RESULTS FROM THE RBDD DATA INSERTION The graphs report the preliminary analysis of patients' data inserted in RBDD database. Information were derived from the clinical questionnaires filled in for each patient sent to the Haemophilia and Thrombosis Centre of Milan. The compilation of the clinical questionnaires is not under our control and we are not responsible for the content (including the accuracy) of any form. The total number includes patients affected by deficiencies of different degrees of severity.
Figure 12	reports the geographic distribution of patients arrived to our Centre. For each country, the number of affected patients is reported.
Figure 13	reports: a •  the number of enrolled probands and families affected by each type of deficiency b •  the prevalence of each type of RBD c •  the percent of RBDs according to different severities.
Figure 14	reports the summary of the genotype characterization: a •  the number of patients already characterized or still under investigation for each RBD b •  the percent of different type of identified mutations